DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Proellex is an investigational drug.
There have been 35 clinical trials for Proellex. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2008.
The most common disease conditions in clinical trials are Myofibroma, Leiomyoma, and Endometriosis. The leading clinical trial sponsors are Repros Therapeutics Inc., Northwestern University, and National Cancer Institute (NCI).
Recent Clinical Trials for Proellex
|An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids||Repros Therapeutics Inc.||Phase 2|
|Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy||National Cancer Institute (NCI)||Phase 2|
|Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy||Northwestern University||Phase 2|